Intrinsic value of Momenta Pharmaceuticals - MNTA

Previous Close

$13.10

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$13.10

 
Intrinsic value

$168.10

 
Up/down potential

+999%

 
Rating

str. buy

 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of MNTA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  22.22
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
  7.33
Revenue, $m
  110
  170
  254
  369
  520
  715
  960
  1,261
  1,622
  2,049
  2,544
  3,111
  3,749
  4,461
  5,245
  6,102
  7,029
  8,025
  9,089
  10,218
  11,412
  12,670
  13,989
  15,371
  16,814
  18,318
  19,885
  21,515
  23,211
  24,972
  26,803
Variable operating expenses, $m
 
  85
  127
  184
  260
  358
  480
  630
  811
  1,024
  1,272
  1,555
  1,875
  2,231
  2,623
  3,051
  3,514
  4,012
  4,544
  5,109
  5,706
  6,335
  6,995
  7,685
  8,407
  9,159
  9,943
  10,758
  11,605
  12,486
  13,402
Fixed operating expenses, $m
 
  135
  139
  142
  146
  149
  153
  157
  161
  165
  169
  173
  178
  182
  187
  191
  196
  201
  206
  211
  216
  222
  227
  233
  239
  245
  251
  257
  264
  270
  277
Total operating expenses, $m
  184
  220
  266
  326
  406
  507
  633
  787
  972
  1,189
  1,441
  1,728
  2,053
  2,413
  2,810
  3,242
  3,710
  4,213
  4,750
  5,320
  5,922
  6,557
  7,222
  7,918
  8,646
  9,404
  10,194
  11,015
  11,869
  12,756
  13,679
Operating income, $m
  -75
  -50
  -12
  42
  114
  208
  327
  473
  650
  860
  1,103
  1,382
  1,697
  2,049
  2,436
  2,860
  3,318
  3,812
  4,338
  4,898
  5,490
  6,113
  6,767
  7,453
  8,168
  8,914
  9,692
  10,501
  11,342
  12,216
  13,125
EBITDA, $m
  -65
  -42
  0
  59
  139
  241
  372
  532
  726
  955
  1,221
  1,526
  1,871
  2,256
  2,680
  3,143
  3,645
  4,184
  4,760
  5,372
  6,019
  6,701
  7,417
  8,166
  8,948
  9,764
  10,614
  11,499
  12,419
  13,375
  14,368
Interest expense (income), $m
  0
  0
  2
  5
  9
  14
  20
  29
  39
  51
  65
  82
  101
  123
  147
  173
  202
  233
  267
  303
  341
  381
  424
  468
  515
  563
  614
  667
  722
  779
  839
Earnings before tax, $m
  -21
  -50
  -14
  37
  106
  194
  307
  445
  611
  809
  1,038
  1,300
  1,596
  1,926
  2,289
  2,686
  3,116
  3,578
  4,071
  4,595
  5,149
  5,732
  6,344
  6,984
  7,653
  8,351
  9,078
  9,834
  10,620
  11,437
  12,286
Tax expense, $m
  0
  0
  0
  10
  29
  53
  83
  120
  165
  218
  280
  351
  431
  520
  618
  725
  841
  966
  1,099
  1,241
  1,390
  1,548
  1,713
  1,886
  2,066
  2,255
  2,451
  2,655
  2,867
  3,088
  3,317
Net income, $m
  -21
  -50
  -14
  27
  77
  142
  224
  325
  446
  590
  758
  949
  1,165
  1,406
  1,671
  1,961
  2,275
  2,612
  2,972
  3,355
  3,759
  4,184
  4,631
  5,099
  5,587
  6,096
  6,627
  7,179
  7,752
  8,349
  8,969

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  353
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  478
  193
  289
  419
  591
  813
  1,091
  1,433
  1,843
  2,328
  2,891
  3,535
  4,261
  5,069
  5,961
  6,934
  7,987
  9,119
  10,328
  11,612
  12,969
  14,397
  15,897
  17,467
  19,107
  20,816
  22,597
  24,449
  26,376
  28,378
  30,458
Adjusted assets (=assets-cash), $m
  125
  193
  289
  419
  591
  813
  1,091
  1,433
  1,843
  2,328
  2,891
  3,535
  4,261
  5,069
  5,961
  6,934
  7,987
  9,119
  10,328
  11,612
  12,969
  14,397
  15,897
  17,467
  19,107
  20,816
  22,597
  24,449
  26,376
  28,378
  30,458
Revenue / Adjusted assets
  0.880
  0.881
  0.879
  0.881
  0.880
  0.879
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
  0.880
Average production assets, $m
  26
  39
  59
  86
  121
  166
  223
  292
  376
  475
  590
  722
  870
  1,035
  1,217
  1,416
  1,631
  1,862
  2,109
  2,371
  2,648
  2,939
  3,246
  3,566
  3,901
  4,250
  4,613
  4,992
  5,385
  5,794
  6,218
Working capital, $m
  357
  6
  9
  13
  19
  26
  35
  45
  58
  74
  92
  112
  135
  161
  189
  220
  253
  289
  327
  368
  411
  456
  504
  553
  605
  659
  716
  775
  836
  899
  965
Total debt, $m
  0
  58
  139
  249
  395
  583
  819
  1,109
  1,457
  1,868
  2,346
  2,892
  3,507
  4,193
  4,949
  5,774
  6,667
  7,627
  8,652
  9,741
  10,891
  12,103
  13,375
  14,706
  16,096
  17,546
  19,056
  20,627
  22,261
  23,958
  25,723
Total liabilities, $m
  106
  164
  245
  355
  501
  689
  925
  1,215
  1,563
  1,974
  2,452
  2,998
  3,613
  4,299
  5,055
  5,880
  6,773
  7,733
  8,758
  9,847
  10,997
  12,209
  13,481
  14,812
  16,202
  17,652
  19,162
  20,733
  22,367
  24,064
  25,829
Total equity, $m
  372
  29
  44
  64
  90
  124
  166
  218
  280
  354
  439
  537
  648
  771
  906
  1,054
  1,214
  1,386
  1,570
  1,765
  1,971
  2,188
  2,416
  2,655
  2,904
  3,164
  3,435
  3,716
  4,009
  4,313
  4,630
Total liabilities and equity, $m
  478
  193
  289
  419
  591
  813
  1,091
  1,433
  1,843
  2,328
  2,891
  3,535
  4,261
  5,070
  5,961
  6,934
  7,987
  9,119
  10,328
  11,612
  12,968
  14,397
  15,897
  17,467
  19,106
  20,816
  22,597
  24,449
  26,376
  28,377
  30,459
Debt-to-equity ratio
  0.000
  1.970
  3.160
  3.910
  4.400
  4.720
  4.940
  5.090
  5.200
  5.280
  5.340
  5.380
  5.420
  5.440
  5.460
  5.480
  5.490
  5.500
  5.510
  5.520
  5.530
  5.530
  5.540
  5.540
  5.540
  5.550
  5.550
  5.550
  5.550
  5.550
  5.560
Adjusted equity ratio
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152
  0.152

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -21
  -50
  -14
  27
  77
  142
  224
  325
  446
  590
  758
  949
  1,165
  1,406
  1,671
  1,961
  2,275
  2,612
  2,972
  3,355
  3,759
  4,184
  4,631
  5,099
  5,587
  6,096
  6,627
  7,179
  7,752
  8,349
  8,969
Depreciation, amort., depletion, $m
  10
  8
  12
  17
  24
  33
  45
  58
  75
  95
  118
  144
  174
  207
  243
  283
  326
  372
  422
  474
  530
  588
  649
  713
  780
  850
  923
  998
  1,077
  1,159
  1,244
Funds from operations, $m
  9
  -42
  -2
  44
  101
  175
  268
  383
  522
  685
  876
  1,093
  1,339
  1,613
  1,915
  2,244
  2,601
  2,984
  3,394
  3,829
  4,288
  4,772
  5,280
  5,812
  6,367
  6,946
  7,549
  8,177
  8,829
  9,508
  10,213
Change in working capital, $m
  1
  2
  3
  4
  5
  7
  9
  11
  13
  15
  18
  20
  23
  26
  28
  31
  33
  36
  38
  41
  43
  45
  48
  50
  52
  54
  56
  59
  61
  63
  66
Cash from operations, $m
  8
  -45
  -5
  40
  96
  168
  260
  372
  509
  670
  858
  1,073
  1,316
  1,587
  1,886
  2,213
  2,568
  2,949
  3,356
  3,788
  4,245
  4,727
  5,233
  5,762
  6,315
  6,892
  7,493
  8,118
  8,768
  9,444
  10,147
Maintenance CAPEX, $m
  0
  -5
  -8
  -12
  -17
  -24
  -33
  -45
  -58
  -75
  -95
  -118
  -144
  -174
  -207
  -243
  -283
  -326
  -372
  -422
  -474
  -530
  -588
  -649
  -713
  -780
  -850
  -923
  -998
  -1,077
  -1,159
New CAPEX, $m
  -6
  -14
  -20
  -27
  -35
  -45
  -57
  -70
  -84
  -99
  -115
  -131
  -148
  -165
  -182
  -199
  -215
  -231
  -247
  -262
  -277
  -292
  -306
  -320
  -335
  -349
  -364
  -378
  -393
  -409
  -425
Cash from investing activities, $m
  80
  -19
  -28
  -39
  -52
  -69
  -90
  -115
  -142
  -174
  -210
  -249
  -292
  -339
  -389
  -442
  -498
  -557
  -619
  -684
  -751
  -822
  -894
  -969
  -1,048
  -1,129
  -1,214
  -1,301
  -1,391
  -1,486
  -1,584
Free cash flow, $m
  88
  -64
  -32
  2
  44
  99
  170
  258
  366
  496
  648
  824
  1,024
  1,248
  1,497
  1,771
  2,069
  2,391
  2,736
  3,104
  3,494
  3,906
  4,339
  4,792
  5,267
  5,763
  6,279
  6,817
  7,377
  7,959
  8,563
Issuance/(repayment) of debt, $m
  0
  58
  81
  110
  146
  188
  236
  290
  348
  411
  477
  546
  616
  686
  756
  825
  893
  960
  1,025
  1,089
  1,151
  1,212
  1,272
  1,331
  1,390
  1,450
  1,510
  1,571
  1,633
  1,698
  1,764
Issuance/(repurchase) of shares, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  1
  58
  81
  110
  146
  188
  236
  290
  348
  411
  477
  546
  616
  686
  756
  825
  893
  960
  1,025
  1,089
  1,151
  1,212
  1,272
  1,331
  1,390
  1,450
  1,510
  1,571
  1,633
  1,698
  1,764
Total cash flow (excl. dividends), $m
  89
  -6
  49
  112
  190
  287
  405
  548
  715
  907
  1,125
  1,369
  1,639
  1,934
  2,253
  2,597
  2,963
  3,351
  3,761
  4,193
  4,645
  5,117
  5,610
  6,124
  6,658
  7,213
  7,789
  8,388
  9,010
  9,656
  10,327
Retained Cash Flow (-), $m
  -2
  -10
  -15
  -20
  -26
  -34
  -42
  -52
  -62
  -74
  -86
  -98
  -110
  -123
  -135
  -148
  -160
  -172
  -184
  -195
  -206
  -217
  -228
  -239
  -249
  -260
  -271
  -282
  -293
  -304
  -316
Prev. year cash balance distribution, $m
 
  353
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  336
  34
  93
  163
  253
  363
  496
  652
  833
  1,040
  1,271
  1,529
  1,811
  2,118
  2,449
  2,803
  3,179
  3,578
  3,998
  4,439
  4,900
  5,382
  5,885
  6,408
  6,953
  7,519
  8,107
  8,717
  9,352
  10,011
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  322
  31
  81
  135
  196
  264
  335
  408
  479
  545
  604
  652
  689
  711
  719
  712
  692
  659
  616
  564
  507
  447
  386
  326
  270
  219
  174
  135
  102
  75
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and M356, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. The company’s novel therapeutics programs include Necuparanib, a novel oncology product candidate derived from heparin; Anti-FcRn program for acute and chronic/intermittent therapies in a range of autoantibody driven diseases; SIF3 program, a novel recombinant protein containing three IgG Fc regions to maximize activity; and hsIVIg, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, Baxalta U.S. Inc., Baxalta GmbH, and Baxalta Incorporated. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

FINANCIAL RATIOS  of  Momenta Pharmaceuticals (MNTA)

Valuation Ratios
P/E Ratio -44.3
Price to Sales 8.5
Price to Book 2.5
Price to Tangible Book
Price to Cash Flow 116.4
Price to Free Cash Flow 465.6
Growth Rates
Sales Growth Rate 22.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 50%
Cap. Spend. - 3 Yr. Gr. Rate -7.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -4.7%
Ret/ On Assets - 3 Yr. Avg. -21.2%
Return On Total Capital -5.7%
Ret/ On T. Cap. - 3 Yr. Avg. -25.4%
Return On Equity -5.7%
Return On Equity - 3 Yr. Avg. -25.4%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -10%
EBITDA Margin - 3 Yr. Avg. -88.4%
Operating Margin -67.3%
Oper. Margin - 3 Yr. Avg. -117.6%
Pre-Tax Margin -19.1%
Pre-Tax Margin - 3 Yr. Avg. -100.6%
Net Profit Margin -19.1%
Net Profit Margin - 3 Yr. Avg. -100.6%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

MNTA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MNTA stock intrinsic value calculation we used $110 million for the last fiscal year's total revenue generated by Momenta Pharmaceuticals. The default revenue input number comes from 2016 income statement of Momenta Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MNTA stock valuation model: a) initial revenue growth rate of 54.5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MNTA is calculated based on our internal credit rating of Momenta Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Momenta Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MNTA stock the variable cost ratio is equal to 50%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $132 million in the base year in the intrinsic value calculation for MNTA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Momenta Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Momenta Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MNTA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MNTA are equal to 23.2%.

Life of production assets of 2.6 years is the average useful life of capital assets used in Momenta Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MNTA is equal to 3.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $372 million for Momenta Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 72.67 million for Momenta Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Momenta Pharmaceuticals at the current share price and the inputted number of shares is $1.0 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
NVS Novartis ADR 73.40 35.44  str.sell
CHRS Coherus BioSci 18.35 0.09  str.sell
BIIB Biogen 272.94 268.16  hold
PFE Pfizer 33.64 29.51  hold
MRK Merck&Co 61.89 29.32  str.sell

COMPANY NEWS

▶ Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat   [Feb-23-17 03:58PM  Motley Fool]
▶ Momenta 4Q Net 60 Cents a Share   [11:05AM  at Investopedia]
▶ Momenta stock rises 4% on corporate update   [08:23AM  at MarketWatch]
▶ 5 Things Mylan's Management Wants You to Know   [Nov-11-16 07:23AM  at Motley Fool]
▶ Why These Biotechs Saw Double-Digit Gains Today   [Nov-09-16 02:25PM  at Motley Fool]
Stock chart of MNTA Financial statements of MNTA
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.